MENU

Expert Voices in Dementia

Expert Voices in Dementia Art

Alzheimer Disease & Dementia

07.14.24

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company

Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab.

More Alzheimer Disease & Dementia Podcasts

Dilemmas in Dementia Art

Dilemmas in Dementia

Explore real-world challenges in dementia practice and strategies to help address these issues. Topics discussed include comorbidities, limited resources and therapeutic options, and an unpredictable clinical course.
Dementia Dialogues art

Dementia Dialogues

Explore real-world challenges in dementia practice and strategies to help address these issues. Topics discussed include comorbidities, limited resources and therapeutic options, and an unpredictable clinical course.

Subscribe to Updates

Sign up to receive alerts and updates from The Neurology Hub.

Thanks for subscribing

CALL FOR CONTRIBUTORS

Do you have cases, images, or other information to share? The Neurology Hub welcomes submissions from clinicians and researchers at all levels.

Contribute Here

More in Alzeheimer DISEASE and Dementia

Caregiver Essentials Dementia Challenges Evaluation & Diagnosis Treatments & Therapies

Subscribe to Updates

Sign up to receive alerts and updates from The Neurology Hub.

Thanks for subscribing

Call for Contributors

Do you have cases, images, or other information to share? The Neurology Hub welcomes submissions from clinicians and researchers at all levels.

Contribute Here